Reuters logo
BRIEF-Revance Therapeutics updates on phase 2 clinical trial results
June 15, 2017 / 12:18 PM / 4 months ago

BRIEF-Revance Therapeutics updates on phase 2 clinical trial results

June 15 (Reuters) - Revance Therapeutics Inc:

* Positive Belmont phase 2 trial results published in dermatologic surgery

* All dose levels of RT002 appeared to be generally safe and well-tolerated

* When compared to placebo, all dose levels of RT002 achieved highly statistically significant efficacy at week 4 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below